(MedPage Today) — Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them.
Many employers and insurers are scaling back coverage of semaglutide (Wegovy) and tirzepatide (Zepbound) and a key government…
Source link : https://www.medpagetoday.com/primarycare/obesity/114375
Author :
Publish date : 2025-02-25 22:10:47
Copyright for syndicated content belongs to the linked Source.
